Evidence map›Paper›PMID 39730952›Full record

Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

The impacts of the COVID-19 pandemic on Australia's myasthenia gravis patients: A self-reported survey study.

Pakeeran Siriratnam, Zhibin Chen, Laura McArthur, Stephen Reddell, WenWen Zhang, Katherine Buzzard

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Unlocking Parkinson's disease: the role of microRNAs in regulation, diagnosis, and therapy.Apoptosis : an international journal on programmed cell death · 2025
    Review
  2. Clinical features of myasthenia gravis with thyroid eye disease: identifying critical gaps and next steps.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pakeeran SiriratnamNeurology Department, Alfred Health, Melbourne, VIC, Australia. p.siriratnam@alfred.org.au.ORCID http://orcid.org/0000-0003-4751-2102
Zhibin ChenDepartment of Neuroscience, The Central Clinical School, Monash University, 55 Commercial Road, Melbourne, VIC, 3004, Australia.
Laura McArthurNeurology Department, Alfred Health, Melbourne, VIC, Australia.
Stephen ReddellBrain and Mind Research Institute, University of Sydney, Camperdown, NSW, 2006, Australia.
WenWen ZhangNeurology Department, Alfred Health, Melbourne, VIC, Australia.
Katherine BuzzardEastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, VIC, 3128, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

aimsPrevious studies have demonstrated high morbidity and mortality in patients with myasthenia gravis (MG) who acquired COVID-19. We aimed to identify the impact of the pandemic on MG disease control, treatment and quality of life.

methodsA prospective observational cohort study was conducted to identify the impact of the COVID-19 pandemic on Australian patients with MG. We conducted an online survey through Myasthenia Alliance Australia from May 2022 to July 2022.

resultsAmong the 229 patients who responded to the survey, most patients had three (80; 34.9%) or four (116; 50.7%) doses of the COVID-19 vaccines, 65 (28.4%) had contracted COVID-19, with 6 patients (9.4%) requiring hospitalisation. A large proportion of patients responded that the pandemic had no impact on their MG disease control (123; 53.7%) or treatment (111; 48.5%). Most patients felt the pandemic had either a mild (111; 48.5%) or moderate (50; 21.8%) impact on their mood.

conclusionOur study provides a snapshot of the types of impacts experienced by myasthenic patients during the pandemic, in particular the psychosocial effects. As we continue to live with COVID-19, clinicians should consider its various impacts in the holistic management of their patients.

Indexed as

COVID-19Myasthenia GravisQuality of LifeAdultAgedAustraliaCOVID-19 VaccinesFemaleHumansMaleMiddle AgedProspective StudiesSelf ReportSurveys and QuestionnairesCOVID-19 VaccinesCOVID-19Mental healthMyasthenia gravisPandemicQuality of life

Identifiers

PMID39730952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.